Introduction

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and
Crohn's disease (CD), is a chronic inflammatory condition of the gastrointestinal (GI) tract. UC is limited to the colon, whereas CD can affect any part of the GI tract from the mouth to the anus (Baumgart and Sandborn, 2007; Gupta et al., 2013) .
Conventional therapeutics for IBD have been associated with multiple adverse effects.
New biologic therapies, including tumor necrosis factor (TNF)-α antagonists (e.g. infliximab, adalimumab and golimumab) and integrin antagonists (e.g. vedolizumab and natalizumab), have profoundly influenced the management of IBD patients.
However, there remain concerns about their potential side effects, tolerability and high costs (Jobin, 2010; Gilroy and Allen, 2014) .
Pregnane X receptor (PXR, NR1I2), one of the members of the nuclear receptor superfamily, is a xenobiotic/metabolic sensor that regulates the expression of drug-metabolizing enzymes and transporters involved in the clearance of many xenobiotic chemicals (Mani et al., 2013; Smutny et al., 2013) . PXR has a bulky and flexible ligand-binding pocket that enables this receptor to accommodate structurally diverse ligands, including prescription drugs, natural products, dietary supplements, environmental pollutants, endogenous hormones and bile acids (Zhang et al., 2008; Cheng et al., 2012) . Ligand-activated PXR regulates the expression of a battery of genes, including phase I metabolic enzymes (cytochrome P450 (CYP) 2B6, CYP2B9, CYP2C8, CYP2C9, CYP3A4 and CYP3A7)), phase II metabolic enzymes (glutathione S-transferases (GSTs), UDP-glucuronosyltransferases (UGTs) and This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on December 3, 2014 as DOI: 10.1124 at ASPET Journals on July 12, 2017 jpet.aspetjournals.org Downloaded from 6 sulfotransferases (SULTs)) and transporters (multidrug resistance protein 1 (MDR1), MDR2, multidrug resistance-associated protein 2 (MRP2) and the organic anion transporter polypeptide 2 (OATP2)). These enzymes and transporters are capable of recognizing a variety of xenobiotics to promote their clearance/detoxification, which is thought to be critical for maintaining intestinal barrier integrity (Zhang et al., 2008; Mencarelli et al., 2010) . Indeed, disruption of the intestinal barrier function is linked to IBD. Gene analysis studies have indicated that the mRNA expression of PXR and MDR1 is significantly reduced in the colons of UC patients (Langmann et al., 2004) .
Others and we have demonstrated that PXR activation inhibits nuclear factor-kappa B (NF-κB) pathway and alleviates the severity of experimental IBD (Cheng et al., 2010; Dou et al., 2012) . In dextran sodium sulfate (DSS)-induced IBD model, administration of pregnenolone-16α-carbonitrile (PCN), a rodent-specific PXR ligand, attenuates development of colitis through decreasing the expression of NF-κB target genes (monocyte chemotactic protein-1 (MCP-1), inducible NO synthase (iNOS), interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α)) and increasing the expression of phase II enzymes (GSTa1, GSTm1 and GSTt1) and transporters (MDR1a and MRP2) (Shah et al., 2007) . Thus, Targeted activation of PXR in recent years has become a therapeutic strategy for IBD (Cheng et al., 2010; Mencarelli et al., 2011) .
Notoginsenoside R1 (R1) is a characteristic constituent of Radix notoginseng, which is a well-known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as cardiovascular disease, cerebral This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on December 3, 2014 as DOI: 10.1124 at ASPET Journals on July 12, 2017 jpet.aspetjournals.org Downloaded from 7 vascular disease and liver dysfunction (Sun et al., 2007; Geng et al., 2010; Fan et al., 2012) . R1 has multiple pharmacological activities, including cardioprotective, neuroprotective, anti-inflammatory and anti-cancer effects (Wang et al., 2009; Sun et al., 2013; Meng et al., 2014) . However, thus far, no study has reported the effect of R1 on IBD. Therefore, in the current study, we utilized in vitro and in vivo models to investigate the effects of R1 on IBD and to uncover the possible underlying mechanisms mediated through PXR activation.
Materials and Methods
Cell lines, reagents, semi-quantitative and real-time quantitative polymerase chain reaction (qPCR), western blot analysis, PXR-mediated NF-κB repression reporter assay, gene silencing, and time-resolved fluorescence resonance energy transfer (TR-FRET) assay details are mentioned in Supplemental Methods.
Mice. Eight-week-old female C57BL/6 mice (20 ± 2 g) were obtained from the Shanghai Laboratory Animal Center and were housed in cages at room temperature (25 ± 2°C) with a 12-h light/dark cycle. Standard mouse chow pellets and water were available ad libitum. The experiments were approved by the Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine.
DSS and Trinitrobenzene Sulfonic Acid (TNBS) Colitis Models in Mice. DSS
or TNBS colitis was induced in mice as described previously (Dou et al., 2012; Dou et al., 2013b) . In brief, 4% (w/v) DSS MP Biomedicals, Solon, OH) was administered in the drinking water (tap water) for 7 days while control mice This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on December 3, 2014 as DOI: 10.1124 at ASPET Journals on July 12, 2017 jpet.aspetjournals.org Downloaded from 8 received tap water only (n=10 mice in each group). In the TNBS model, food (but not water) was withdrawn overnight prior to TNBS (Sigma-Aldrich, MO, USA) administration. Colitis was induced by slowly and continuously intrarectal administration of a 0.1 ml of 50 % ethanol solution containing 2.5 mg TNBS. Solvent alone (0.1 ml of 50% ethanol) was administered in control group. Mice received a daily gavage of R1 (25 mg/kg) in 0.5% methylcellulose from day 1 to day 7. R1 dosage was selected based on the results of a previous report in which 25 mg/kg of R1 pretreatment blocked NF-κB activation and the subsequent myocardial inflammation and apoptotic responses in endotoxemic mice (Sun et al., 2013) . Mice IBD studies were repeated again for independent confirmation of the initial data.
Assessment of Colitis.
The severity of diarrhea was monitored throughout the experimental period. The total length of the colon was measured after sacrifice of the mice under anesthesia. The distal colon was fixed in 10% buffered formalin, embedded in paraffin and processed for routine hematoxylin and eosin (H&E) staining of sections. Histological scoring was performed in a blinded fashion by two pathologists to obtain a combined score of inflammatory cell infiltration (score 0-3) and tissue damage (score 0-3) as described previously (Dou et al., 2013b) . of the control cells as described (Dou et al., 2012) .
Measurement of Cytokines.
Colon segments were homogenized in ice-cold PBS.
The homogenates were centrifuged at 3,000 g for 10 min and the supernatants were assayed for the determination of levels of TNF-α and IL-6 as described previously (Dou et al., 2013a) . The level of each cytokine was evaluated using ELISA kits according to the manufacturer's protocols (R&D systems, Minneapolis, MN, USA) and the results are expressed in pg/mg of protein in each sample.
Myeloperoxidase ( inflammation. MPO activity in colon tissues was measured as previously described and the values were expressed as units/mg of protein.
Statistical Analysis. All of the data are expressed as the mean values ± SD. The differences between the groups were analyzed using one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post-hoc test.
The statistical analyses were performed using the SPSS 16.0 software package. The value of p < 0.05 was considered statistically significant.
Results
R1 Ameliorated DSS-induced Colitis. The DSS-induced colitis model is a well-established chemical IBD model with clinical features resembling human UC
(Neurath and Travis, 2012). R1 treatment significantly ameliorated the DSS-induced loss of body weight, bloody diarrhea, colon shortening and histological damage ( Fig.   1 ). The activity of MPO as well as the levels of TNF-α and IL-6 were markedly reduced by R1 treatment (Table 1 ). In addition, none of the mice that received R1 alone exhibited loss of body weight, diarrhea, colon shortening or mucosal disruption at any point during the study.
R1 Inhibited NF-κB Activation and Downregulated NF-κB Target Gene
Expression. Intestinal NF-κB avtivation plays a central role in the pathogenesis of IBD (Atreya et al., 2008) . Major steps for NF-κB activation involve the activation of IκB kinase (IKK)-α/ß, which is followed by IκBα degradation and the subsequent p65/p50 nuclear translocation (Manzoor and Koh, 2012) . Using western blot analysis,
we observed a phosphorylation/activation of IKK-α/ß and p65 in the colonic tissue of DSS-treated mice ( Fig Next, we investigated whether R1 affects the expression of NF-κB target genes in RAW264.7 mouse macrophage cells using semi-quantitative RT-PCR. RAW 264.7 macrophage cell line is a well-established model system for inflammatory studies (Wu et al., 2011) . In accordance with in vivo data, R1 treatment obviously decreased the expression of iNOS, ICAM-1, MCP-1, COX2, IFNγ, TNF-α and IL-15 in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells (Fig. 3A) .
R1 Activated both Human and Mouse Wild-type PXR. In transient transfection
gene reporter assays, R1 increased human or mouse PXR-mediated CYP3A4
promoter transcription in a concentration-dependent manner (Fig. 3B ). In addition, rifampicin and PCN significantly activated human and mouse PXR, respectively.
R1 Inhibited NF-κB Activity in a PXR-dependent Manner. To determine
This article has not been copyedited and formatted. The final version may differ from this version. . In cells transfected with the NF-κB-luciferase reporter and the PXR mock, treatment with the known NF-κB pathway activator TNF-α led to increased NF-κB activity; however, R1 had no effect on NF-κB activity in the absence of human PXR expression (Fig. 4A ).
In cells transfected with the NF-κB-luciferase reporter and the human PXR expression vector, TNF-α-stimulated NF-κB activity was significantly inhibited by R1 in the presence of human PXR expression. To further demonstrate that PXR is specifically involved in the suppression of NF-κB by R1, PXR siRNA transfection was conducted in above HT-29 cells, which had been previously transfected with the NF-κB-luciferase reporter and the human PXR expression plasmid. As expected, the regulatory effect of R1 on TNF-α-stimulated NF-κB activity was abrogated (Fig. 4B ).
R1 Upregulated the Expression of Xenobiotic-metabolizing Genes in vitro
and in vivo. PXR target genes are critical components in the intestinal barrier function against xenobiotics and bacteria (Langmann et al., 2004; Mencarelli et al., 2010 ). In the current study, we observed a robust upregulation of the expression of CYP3A11, UGT1A1 and MDR1a in the colons of mice that received 7 days of R1 treatment (Fig.   5A ). Consistent with the in vivo results, an increase in the expression of CYP3A4, UGT1A1 and MDR1a was observed in LS174T cells exposed to R1 treatment (Fig.   5B ).
R1 Upregulated the Expression of Xenobiotic-metabolizing Genes in a
This article has not been copyedited and formatted. The final version may differ from this version. 6A ), which is consistent with the results of previous reports (Wang et al., 2008; Venkaresh et al., 2011) . In addition, both rifampicin and R1 activated the wild-type human PXR, whereas none of them activated either double or triple mutant. Table 1 ). Oral R1 administration significantly improved these parameters and ameliorated the histological pathology.
Confirmation of the PXR-binding
No significant changes were observed in vehicle and R1-treated normal mice.
Discussion
Chemically induced colitis models have been developed and extensively used to rectal administration of TNBS dissolved in ethanol induced severe colitis in mice and that R1 treatment reduced the extents of histological damage and colon shortening.
Since no report about the effect of R1 on UC or CD has been available, our findings are unique in establishing the role of R1 in ameliorating the UC-or CD-like features in murine models of IBD. Notably, none of the mice that received R1 alone exhibited apparent body weight loss, diarrhea, colon shortening or mucosal disruption throughout this study, indicating the relative safety of the R1 treatment.
Recent studies have shown that PXR is involved in the pathogenesis of IBD (Cheng et al., 2010; Cheng et al., 2012) . Loss of PXR function has been associated with intestinal inflammation in animal models (Cheng et al., 2010; Dou et al., 2012) . PXR and its target genes are necessary to maintain the integrity of the intestinal epithelial barrier (Shah et al., 2007) . In this study, we found that R1 upregulated the expression of CYP3A, UGT1A1 and MDR1a, and this effect was mediated by PXR.
It was recently reported that natural compound curcumin decreases the susceptibility of MDR1a-/-mice to spontaneous colonic inflammation through PXR activation (Liu and Wang, 2011). In our study, we found that R1 treatment not only decreased the proteins of p-IKK-α/ß, p-IκBα and p-p65, but also downregulated the pro-inflammatory genes expression, and reduced the activity of MPO and the accumulation of TNF-α and IL-6. Further studies indicated that R1 decreased the activity of NF-κB in a PXR-dependent manner. In fact, recent molecular and pharmacological studies have revealed a mutual suppression between PXR and the NF-κB signaling pathway (Xie and Tian, 2006; Wahli, 2008) . High NF-κB activity inhibits the activation of PXR (Gu et al., 2006) , whereas PXR activation suppresses the activity of NF-κB and the expression of its target genes (Zhou et al., 2006) .
IBD is associated with a considerable reduction in the quality of life of the patients, and currently no curative treatment is available (van der Marel et al., 2011; Gupta et al., 2013) . The use of medicinal plants or their active components is becoming an increasingly attractive approach for the management of IBD (Shin et al., 2009; Zhang et al., 2014) . In the present study, as a part of our on-going screening program to evaluate the anti-inflammatory potentials of natural compounds (Dou et al., 2013a , we investigated the anti-inflammatory effects of R1 on DSS-or TNBS-induced colitis. To our knowledge, for the first time, the present study (B) The levels of the expression of NF-κB target genes in colon samples isolated from mice (n = 6 per group) were determined using qRT-PCR. The levels of expression are normalized to that of ß-actin, and each bar represents the mean value ± SD of two independent experiments performed using samples in triplicate. * p < 0.05, ** p < 0.01 vs. DSS-treated group. DSS/TNBS+R1 61.5 ± 3.9 ** 164.2 ± 16.6 * 11.4 ± 1.8 ** 52.2 ± 4.1 ** 86.3 ± 7.4* 8.8 ± 0.7 * Colon segments from mice (n = 6 per group) were excised and homogenized. The supernatants were assayed for the determination of the activity of MPO and the levels of TNF-α and IL-6 as described in the Materials and Methods. Values are expressed as the mean ± SD. * p < 0.05, **P < 0.01 vs. DSS-or TNBS-treated group.
